AFATINIB IN THE TREATMENT OF METASTATIC AND LOCALLY ADVANCED LUNG ADENOCARCINOMA WITH EGFR MUTATIONS: NEW SIDES STUDIED POSSIBILITIES

A reasonable strategy for drug therapy of non-small-cell lung cancer  (NSCLC) with activating mutations of EGFR is the use of tyrosine kinase inhibitors (TKI) in front-line therapy, providing a two-fold increase in life expectancy for patients with metastatic or locally advanced form of the disease....

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	E. V. Karabina, L. N. Lubchenko, M. M. Davydov
Formaat:	Artigo
Taal:	Russo
Gepubliceerd in:	Remedium Group LLC 2017-11-01
Reeks:	Медицинский совет
Onderwerpen:	locally advanced and metastatic non-small cell lung cancer adenocarcinoma of the lung tyrosine kinase inhibitors of egfr egfr-activating mutations targeted therapy resistance afatinib
Online toegang:	https://www.med-sovet.pro/jour/article/view/2166
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!